Montelukast Bgr

Montelukast, the active ingredient in Montelukast Bgr, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Bgr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on leukotriene pathways to manage chronic respiratory allergic conditions.

Asthma: improves long‑term control and reduces the frequency of exacerbations. Allergic rhinitis: relieves nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Mood changes, including depression or suicidal thoughts

When prescribing Montelukast, consider the following safety measures.

Assess asthma control before initiating: ensure the patient is on appropriate inhaled therapy. Monitor for neuropsychiatric symptoms: report any mood changes or suicidal thoughts promptly. Use caution in patients with hepatic impairment: dose adjustment may be required. Avoid use in patients with known hypersensitivity to montelukast. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Phenobarbital: may reduce plasma concentrations of montelukast. - Rifampin: can decrease therapeutic efficacy. - Ketoconazole: may increase montelukast levels.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Beta‑agonists: additive bronchodilatory effect may enhance symptom relief.